Cargando…
Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
Effective treatments for androgen-independent prostate cancer (AIPCa) are lacking. To address this, emerging therapeutics such as proteasome inhibitors are currently undergoing clinical trials. Inositol hexakisphosphate (IP6) is an orally non-toxic phytochemical that exhibits antitumour activity aga...
Autores principales: | Diallo, J-S, Betton, B, Parent, N, Péant, B, Lessard, L, Le Page, C, Bertrand, R, Mes-Masson, A-M, Saad, F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584963/ https://www.ncbi.nlm.nih.gov/pubmed/18941459 http://dx.doi.org/10.1038/sj.bjc.6604730 |
Ejemplares similares
-
Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer
por: Betton, Blandine, et al.
Publicado: (2011) -
Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022) -
Inositol hexakisphosphate is required for Integrator function
por: Lin, Min-Han, et al.
Publicado: (2022) -
Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate
por: Bizzarri, Mariano, et al.
Publicado: (2016) -
Inositol hexakisphosphate increases the size of platelet aggregates
por: Brehm, Maria A., et al.
Publicado: (2019)